IPSEN Change in Accounts Receivable 2016-2024 | IPSEY

IPSEN change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • IPSEN annual change in accounts receivable for 2024 was $-0.049B, a 2730.2% increase from 2023.
  • IPSEN annual change in accounts receivable for 2023 was $-0.002B, a 98.11% decline from 2022.
  • IPSEN annual change in accounts receivable for 2022 was $-0.091B, a 14.86% increase from 2021.

IPSEN Change in Accounts Receivable 2016-2024 | IPSEY

  • IPSEN annual change in accounts receivable for 2024 was $-0.049B, a 2730.2% increase from 2023.
  • IPSEN annual change in accounts receivable for 2023 was $-0.002B, a 98.11% decline from 2022.
  • IPSEN annual change in accounts receivable for 2022 was $-0.091B, a 14.86% increase from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.7B
Daiichi Sankyo, - (DSNKY)$45.3B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$17.6B
Merck (MKKGY)$16.4B
Shionogi (SGIOY)$14.6B
Neurocrine Biosciences (NBIX)$13.8B
United Therapeutics (UTHR)$13.7B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$8.9B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Procaps Group, S.A (PROCF)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B
Dyne Therapeutics (DYN)$1.9B